BioNxt Solutions Inc.
BNXT
CNSX
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 12.50K | 900.00 | 3.10K | 14.40K | 4.30K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 12.50K | 900.00 | 3.10K | 14.40K | 4.30K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 12.50K | 900.00 | 3.10K | 14.40K | 4.30K |
| SG&A Expenses | 612.70K | 307.50K | 650.10K | 717.20K | 381.80K |
| Depreciation & Amortization | 16.90K | 16.70K | 17.20K | 31.60K | 36.10K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 979.90K | 526.00K | 998.80K | 1.46M | 809.40K |
| Operating Income | -967.40K | -525.20K | -995.70K | -1.45M | -805.10K |
| Income Before Tax | -1.07M | -712.10K | -1.17M | -1.81M | -1.05M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.07M | -712.10K | -1.17M | -1.81M | -1.05M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.07M | -712.10K | -1.17M | -1.81M | -1.05M |
| EBIT | -967.40K | -525.20K | -995.70K | -1.45M | -805.10K |
| EBITDA | -950.50K | -508.50K | -978.50K | -1.42M | -769.00K |
| EPS Basic | -0.01 | -0.01 | -0.01 | -0.02 | -0.01 |
| Normalized Basic EPS | -0.01 | 0.00 | -0.01 | -0.01 | -0.01 |
| EPS Diluted | -0.01 | -0.01 | -0.01 | -0.02 | -0.01 |
| Normalized Diluted EPS | -0.01 | 0.00 | -0.01 | -0.01 | -0.01 |
| Average Basic Shares Outstanding | 113.02M | 109.74M | 108.99M | 105.56M | 98.82M |
| Average Diluted Shares Outstanding | 113.02M | 109.74M | 108.99M | 105.56M | 98.82M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
